Leo Pharma halts development of tablet treatment for atopic eczema
In a phase IIa/b study, Leo Pharma has tested a potential new tablet treatment for moderate to severe atopic eczema, but is now stopping the development of the candidate, the pharmaceutical company writes in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.